Behavioral & Cognitive Disorders
Apr. 12, 2022
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
The beneficial effect of physostigmine, a cholinesterase inhibitor, on myasthenia gravis was first described by Mary Broadfoot Walker in 1934 (28). Physostigmine was soon replaced by prostigmine because of its side effects (29). Prostigmine remained the primary drug for myasthenia gravis until the 1950s when it was replaced by its analog, pyridostigmine. Pyridostigmine has a longer duration of action and fewer muscarinic side effects than does prostigmine. It is marketed for the treatment of myasthenia gravis. Even though data from well controlled clinical trials to support its clinical use are lacking, pyridostigmine is the most used first-line therapy for myasthenia gravis based on its use in practice for over 50 years (18). In 2003, the FDA approved pyridostigmine for use by the military for increasing troops' chances of surviving exposure to the nerve gas soman. Because no human trials have been done, the approval was based on reviewing effectiveness studies in animals.
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.